Updated August 25, 2018 12:05:03The announcement that the accord manufactures pharmaceuticals was a major deal for Pfizer.
The company will be the first US pharma company to manufacture and distribute its products in the region.
Pfizer is also the first pharmaceutical company to sell directly to US consumers.
The deal will be a boon for Pfizners US operations and for Pfiizners global brand.
The company said that it plans to invest $1.8 billion to support research and development, and expand its clinical trial network in Asia and Latin America.
The agreement was also good news for pharma giants such as Pfizer and AstraZeneca, whose subsidiaries have been struggling with the cost of developing medicines.
In addition, the deal will also help Pfizer to increase its manufacturing capacity in Europe, as the region has been the main hub for the development of Pfizner’s medicines.
Pfizer and its subsidiaries were previously the only companies that could manufacture and sell drugs in the US.
Pfizers drug production facility is located in the state of New Jersey.
The pact will provide Pfizs US operations with an additional $3.1 billion in cash and cash equivalents, including $2.1 million of cash from the sale of the company’s drug manufacturing unit.
The accord will also provide Pfizer with more than $2 billion in tax-free cash, the company said in a statement.
The accord has also provided the company with a tax deduction of $5.1-$6 billion for the first two years.
Since its launch, Pfizns sales have increased, and the company expects to reach $30 billion by 2020, with the rest of its business to be profitable by 2021.